Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Finlabo SIM Spa
$10.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Announces Phase 3 Results for Investigational New Insulin U300


Saturday, 22 Jun 2013 11:00am EDT 

Sanofi SA announced that the first phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus (insulin glargine [rDNA origin] injection). The Company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus. 

Company Quote

87.84
 --
5 Mar 2015